Takeda Continues To Shed Pipeline Assets In Roivant Deal
This article was originally published in PharmAsia News
Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.
You may also be interested in...
Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.
Axovant was Roivant's star and the first test of its risk-reducing strategy, but the company will attempt to move its spotlight to other assets at an R&D day on July 10. Ahead of the event, Roivant announced a reorganization to strengthen its subsidiaries and accelerate the creation of new ones.